Create your personal agenda –check the favourite icon
Gene-modified cell therapies remain trapped in a high-cost, low-throughput paradigm, with ~40,000 patients treated to date versus the million-plus we must reach in the next decade. Solving the challenge demands new thinking. By fusing advanced analytics and agentic AI with proven playbooks from retail/CPG, automotive, agriculture, and fashion industries, we can compress vein-to-vein time, reduce costs, and enable quality at scale.
This session distils those insights into a five-step roadmap—people, process, data, tech, culture—to develop a scalable, adaptive value chain ready for the next million patients.
Gene-modified cell therapies remain trapped in a high-cost, low-throughput paradigm, with ~40,000 patients treated to date versus the million-plus we must reach in the next decade. Solving the challenge demands new thinking. By fusing advanced analytics and agentic AI with proven playbooks from retail/CPG, automotive, agriculture, and fashion industries, we can compress vein-to-vein time, reduce costs, and enable quality at scale.
This session distils those insights into a five-step roadmap—people, process, data, tech, culture—to develop a scalable, adaptive value chain ready for the next million patients.
Advanced therapies bring exciting possibilities — but also new safety challenges.
In this session, PharSafer will explore how vigilance practices must evolve to keep pace with ATMP innovation. From delayed risks to lifecycle monitoring, the talk outlines modern, long-term safety frameworks that support both regulatory success and patient confidence. With a focus on practical solutions, it also highlights how industry collaboration can drive scalable, cost-effective approaches to safety in this rapidly advancing space.
Create your personal agenda –check the favourite icon